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Tumor microvasculature possesses a high degree of heterogeneity in its structure and function. These features have been
demonstrated to be important for disease diagnosis, response assessment, and treatment planning. The exploratory eﬀorts of
quantifying tumor vascular heterogeneity with DCE-MRI have led to promising results in a number of studies. However, the
methodological implementation in those studies has been highly variable, leading to multiple challenges in data quality and
comparability. This paper reviews several heterogeneity quantiﬁcation methods, with an emphasis on their applications on
DCE-MRI pharmacokinetic parametric maps. Important methodological and technological issues in experimental design, data
acquisition, and analysis are also discussed, with the current opportunities and eﬀorts for standardization highlighted.
1.Introduction
Development of novel antiangiogenic agents has posed a
new challenge to medical imaging technologies. Unlike
the systemic cytocidal eﬀect of traditional cytotoxic drugs,
these new agents are selectively targeted to the endothelial
cells of tumor neovasculature, inducing a rapid shutdown
of tumor blood supply without substantially aﬀecting any
morphologic metric [1]. Their cytostatic nature makes the
conventionalmethodoftumorsizemeasurementinadequate
for response evaluation. Several molecular and functional
imaging techniques, namely, dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) [2, 3], positron
emission tomography (PET) [2, 4], and dynamic contrast
enhanced computed tomography (DCE-CT) [2, 5], have
been developed in response to this challenge by monitoring
pathophysiologic changes in various aspects of tumor vascu-
lar structure and functionality.
Among these imaging techniques, DCE-MRI has the
unique advantage of not using ionizing radiation. Con-
sequently, its repeated use in response assessment is not
limited by patient dose considerations [2, 6]. In fact, daily
or weekly repeats of DCE-MRI examinations are common
in preclinical and clinical studies, allowing researchers to
capture rapid change in tumor vasculature during the
short “normalization window” after administration of an
antiangiogenic agent [7]. Moreover, the wide availability of
MR scanners makes this technique easily accessible to both
clinicians and patients. As of September, 2010, American
CollegeofRadiology(ACR)hasaccredited5498MRfacilities
in the United States, compared to only 963 ACR-accredited
PET facilities. All these advantages make DCE-MRI a
convenient yet ﬂexible modality for noninvasive evaluation
of tumor microvasculature and angiogenesis. It has been
applied to many preclinical studies and early phase clinical
trials of various antiangiogenic and antivascular agents, as
well as in nontrial settings for tumor grading and clinical
outcome prediction [8, 9]. Quantitative imaging biomarkers
derived from pharmacokinetic modeling of DCE-MRI data
have been demonstrated to be correlated with various
physiologic and pathophysiologic parameters in human and
animal models, and found to be predictive of response rate
and progression in patients accepting PTK/ZK treatment
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Although preclinical and clinical results have shown that
DCE-MRI is a powerful technique for the detection of subtle
changes in tumor vascular function, many improvements
are still needed for this technique to reach its maximum
potential. Particularly, the important issue of tumor vascular
heterogeneity needs to be addressed. Heterogeneous distri-
bution of neovasculature has been reported in almost all
types of solid tumor [12–14]. This phenomenon reﬂects the
more fundamental heterogeneity in the clones of diﬀerent
tumor cell genomic subtypes and the expression of various
pro- and antiangiogenic genes [15–17]. Experimental evi-
dence shows that tumor vascular heterogeneity is associated
withdiseaseprogressionandmalignancy[18].Recentstudies
suggest that cancer relapse and metastasis are likely to be
governed by a small population of cancer stem cells in
aberrant vascular niches [19–21]. This new understanding
strongly implies tumor vascular heterogeneity may have key
importance for the understanding of disease mechanism and
the discovery of novel treatment strategies. However, so far
this critical information was simply ignored or only brieﬂy
mentioned as qualitative description in most preclinical and
clinical studies. Even in the limited number of cases where
quantiﬁcation eﬀorts have been made, substantial discrep-
ancies exist in quantiﬁcation method, parameter choice,
and result interpretation. This lack of consensus has greatly
hindered the investigation of tumor vascular heterogeneity
and its inﬂuence on treatment response with DCE-MRI.
In this paper, we critically review diﬀerent quantiﬁcation
methods for heterogeneity currently available in the litera-
ture, and discuss several methodological and technological
issues that are important in assessment of tumor vascular
heterogeneity. Although these methods can be applied to
any DCE-MRI image or parametric map, we emphasize
their application on pharmacokinetic parametric maps as
pharmacokinetic modeling is the most advanced DCE-MRI
data analysis approach that provides pathophysiologically
meaningful quantitative interpretation of DCE-MRI data.
2. ImagingTumor Vascular
Heterogeneitywith DCE-MRI
In most solid tumors, the neovasculature developed through
angiogenesis has an abnormal structure, with defects on
walls that make them more permeable than normal vessels.
As blood carrying a low molecular weight contrast agent
(such as Gadopentetate Dimeglumine) ﬂows through tumor
vasculature, the contrast agent molecule leaks into the
interstitial space and accumulates there. Interaction between
the paramagnetic Gd3+ ion and adjacent water protons
enhances tissue longitudinal (T1) relaxation rate, generating
a brighter signal in T1-weighted images. The magnitude and
rate of signal enhancement are determined by tissue vascular
fraction, perfusion, microvascular permeability, and relative
volume of the extracellular extravascular space (EES). The
brightness information can be converted to contrast agent
concentration with the linear relationship between gadolin-
ium concentration and T1 relaxation rate [27]. The dynamic
change of contrast agent concentration can be described by
variousmodel-freeparametersorﬁttedtoapharmacokinetic
model(Figure 1)[22–26],yieldingparametricmapsthatgive
an intuitive and quantiﬁable illustration of tumor vascular
heterogeneity. The most commonly used pharmacokinetic
and model-free parameters are summarized in Tables 1
and 2, using the standard nomenclature proposed in the
consensus paper by Tofts et al. [28]. Details about the use
and interpretation of these parameters are beyond the scope
of this paper. Interested readers are referred to the in-depth
reviews written by Tofts et al. [28] and Evelhoch [29].
Heterogeneity in tumor vasculature is subject to change
over time. During tumor growth, proliferation of tumor
cells is faster than angiogenesis, leading to the formation of
poorly perfused hypoxic zones near the tumor center. Rim
enhancement is frequently observed in DCE-MRI images of
various types of primary cancers, metastases, and xenografts.
In the breast, it is a strong indicator of cancer in small
lesions and malignancy in larger masses [18]. Other more
complicated patterns of enhancement are also common.
In general, fast progressing diseases and malignancies are
associated with highly heterogeneous enhancement patterns
in DCE-MRI images. This feature can be used to facilitate
cancer diagnosis and staging. In human gliomas, Rose et
al. found that low- and high-grade tumors are signiﬁ-
cantly diﬀerent in several spatial heterogeneity statistics of
DCE-MRI pharmacokinetic parameters [35, 36]. In breast
imaging, diﬀerent internal enhancement patterns have been
identiﬁed as an important diagnostic characteristic by the
ACR Breast Imaging-Reporting and Data System (BI-RADS)
MRI lexicon [18].
In cancer treatment, tumor heterogeneity is usually
associated with poor response, a higher chance of developing
metastasis, and substantially shorter progression-free and
overall survival [37,38].Themechanismisprobablythrough
the selection of more aggressive tumor cells that can better
tolerate the hostile acidic, hypoxic environment in poorly
perfusedlow-enhancingregions[19,39].Treatment-induced
changes in tumor vascular heterogeneity have been reported
in several preclinical and clinical settings. Checkley et al.
observed that in human PC-3 prostate adenocarcinoma
xenografts receiving ZD6474 treatment, the core region in
the xenograft tumor revealed a larger reduction in the
pharmacokinetic parameter Ktrans than the enhancing rims,
suggesting a change in the distribution patterns of perfusion
and permeability [40]. De Lussanet et al. found that pri-
mary rectal cancer patients receiving radiation therapy have
lower intratumoral heterogeneity in the pharmacokinetic
parameters Ktrans and vp than patients without radiation
therapy [41]. Several groups also explored the possibility
of predicting treatment eﬃcacy with tumor vascular het-
erogeneity and its early change. Johansen et al. investigated
the relationship between the distributions of DCE-MRI
model-free parameters and patient 5-year survival in a small
cohort of 24 breast cancer patients receiving neoadjuvant
chemotherapy. They found that patients surviving for more
than 5 years have signiﬁcantly less heterogeneous relative
signal intensity (RSI) distribution than nonsurvivors in the
baseline DCE-MRI study performed prior to the start of
therapy[30].Inasimilarstudy,Padhanietal.correlatedearlyJournal of Biomedicine and Biotechnology 3
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Figure 1: In the literature, several models are available for DCE-MRI pharmacokinetic analysis. The Tofts’ model ((a), also known as Kety’s
o rL a r s s o n ’ sm o d e l )[ 22] models the gadolinium concentration dynamic change in a tissue voxel as the result of convolution between an
exponentialkernelandameasuredorassumedarterialinputfunction(AIF).Aplasmatermwithvolumefractionvp isaddedintheextended
Toft’s model (b)[23] by the assumption that the inﬂuence of the intravascular compartment is nonnegligible. The Brix’s model (c) [24] takes
thegadoliniumconcentrationinbloodplasmaasanotherunknownvariableandsolvesitwiththetissuedynamiccurvefromasetofordinary
diﬀerential equations. In the adjusted Brix’s model (d) [25], an oversimpliﬁed assumption in the original Brix’s model is corrected, leading
to a more realistic description of the plasma signal. In the reference region model (e) [26], two dynamic curves are simultaneously measured
from the target voxel and a nearby reference region with known Ktrans and ve values. The need for an AIF is eliminated by jointly solving two
pharmacokinetic equations for target voxel and reference region.
changes in the distribution of DCE-MRI pharmacokinetic
parameters with treatment response assessment. Changes
in vascular heterogeneity quantiﬁed by the range of Ktrans
distribution at the end of cycle two were found to be
predictiveofbothclinicalandhistopathologicresponsesafter
three to six cycles of therapy [42]. Yuh et al. analyzed serial
DCE-MRI studies of 101 patients during early treatment
of cervical cancer. Part of their data has low temporal
resolution so a complete pharmacokinetic analysis was not
possible. Tumor vascular heterogeneity was thus quantiﬁed
by the lower percentiles of voxel signal intensities in the
plateau phase of the dynamic curves. Low values of the
5th to 20th percentiles were found to be correlated with
poor primary tumor control and short disease-free survival.
The 5th percentile measured at 2–2.5 weeks of therapy
provided the best prediction for 8-year primary tumor
control [43].
3. QuantifyingTumor Vascular Heterogeneity
For a long time, radiologists identify intratumoral het-
erogeneity solely by their visual perception of the image.
Even though some level of consensus can be achieved
with stringent training of readers and standardization of
descriptive vocabularies, this approach is still subjective.
Many factors, like the imaging hardware, personal bias, or
even the physical condition of the reader, can aﬀect the
readers’ judgement and lead to intra- and interobserver
variationsinassessment[44].Thisproblemisnowbecoming
even more meaningful with the development of novel
quantitative imaging techniques like DCE-MRI and perfu-
sion CT. These techniques introduce a new dimension of
spatially resolved functional information into the data space,
which is usually displayed as pseudocolor overlays on the
conventional morphologic images. Human color perception,4 Journal of Biomedicine and Biotechnology
Table 1: Pharmacokinetic parameters often used in DCE-MRI pharmacokinetic analysis.
Parameter Deﬁnition Units Alternative names Literature
Ktrans Volume transfer constant between EES and blood plasma min−1 EF, KPS [22, 23, 26]
ve EES volume per unit tissue volume N/A Interstitial space [22, 23, 26]
vp Blood plasma volume per unit tissue volume N/A [23]
kep Rate constant from EES to blood plasma min−1 k21 [22–26]
kpe Rate constant from blood plasma to EES min−1 k12 [25]
kel Elimination rate constant min−1 [24, 25]
Amp Amplitude of the normalized dynamic curve N/A A [24, 25]
Table 2: Model-free parameters often used for DCE-MRI dynamic curve description†.
Parameter Deﬁnition Units Alternative names Literature
Area-under-the-curve (AUC) Area under the signal intensity or
gadolinium dynamic curve
a.u·min or
mmol·min/L IAUC, AUGC, IAUGC [29]
Relative signal intensity (RSI) RSI = S(t)/S0 N/A [30]
Initial slope Maximum or average slope in the
initial enhancement a.u./min Enhancement slope, upslope,
enhancement rate
[31]
Washout slope Maximum or average slope in the
washout phase a.u./min Downslope, washout rate [32]
Peak enhancement ratio (PER) PER = (Smax −S0)/S0 N/A Maximum signal enhancement
ratio (SERmax)
[33]
Tmax
Time from contrast agent arrive
to peak enhancement s Time-to-peak (TTP)
Maximum intensity-time ratio (MITR) MITR = PER/Tmax s−1 [34]
†Unlike the pharmacokinetic parameters, the nomenclature for model-free parameters has not been standardized.
Notation and abbreviations: S(t): MR signal intensity at time t; S0: precontrast signal intensity; Smax: maximum signal intensity; a.u.: arbitrary unit.
however, is both nonlinear to luminance and nonuniform
for diﬀerent colors. As demonstrated by Giesel et al., reader’s
perception of intratumoral homogeneity/heterogeneity can
easily be exaggerated or understated by simply choosing a
diﬀerent display range or color scheme (Figure 2)[ 45, 46].
In order to tackle this problem, several alternative methods
have been developed by researchers in diﬀerent branches
of science. All these methods are quantitative, seeking to
extractasetofwell-deﬁnedquantitiesratherthanambiguous
verbaldescriptions tosummarizesomekeyfeaturesoftumor
vascular heterogeneity.
In this section, we review these methods in separate top-
ics. Technological issues and methodological considerations
that we deem important in study design and data acquisition
and analysis will be discussed in the next section.
3.1. Subregional Region-of-Interests (ROIs). A simple,
straightforward strategy for dealing with intratumoral
heterogeneity is to subdivide the tumor into regions with less
spatial variability. In the breast, many researchers prefer to
analyzeasmallregionwiththehighestenhancement(i.e.,the
“hot-spot”) instead of the whole tumor. If the hot-spot ROI
is small enough and correctly placed, the hot-spot average is
equivalent to the maximum of the whole tumor histogram.
The hot-spot analysis can be performed semiautomatically,
thus reducing the observer-related variability in ROI
placement [34, 47]. In an early study, Mussurakis et al. were
unable to detect a statistically signiﬁcant diﬀerence in peak
enhancement ratio (PER) between 71 malignant and 37
benign lesions, and concluded that hotspot analysis may
not provide any diagnostic advantage over the whole-tumor
method [33]. However, their result is probably undermined
by an inappropriate selection of parameter: it is now known
that in DCE-MRI, the most profound diﬀerence between
malignant and benign breast lesions is not the maximum
signal enhancement, but the shape of the entire dynamic
enhancement curve. Malignant tumors have a quick uptake
of contrast agent. Their dynamic curves are characterized
by a fast increase to the peak followed by a slow washout or
a stable “plateau”. Benign lesions usually have a persistently
increasing dynamic curve in which the maximum signal
intensity is achieved by the end of the observation window
[48]. Liney et al. took this factor into consideration by
introducing a new model-free parameter, the maximum-
intensity-time-ratio (MITR),thatcorrectsPERwiththetime
to peak enhancement (Tmax). Their results from a study of
similarsize(81malignantand36benignlesions)agreedwith
Mussurakis et al. conclusion about PER, but also showed
that the lesion diﬀerentiation ability of the hot-spot analysis
is signiﬁcantly improved over the whole-tumor method
when MITR is used [34]. Other parameters that have beenJournal of Biomedicine and Biotechnology 5
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Figure 2: Visual assessment of tumor vascular heterogeneity on a pseudocolor map is inherently subjective: the same parametric map of the
pharmacokinetic parameter Ktrans is visualized as pseudocolor overlays with diﬀerent display ranges and color schemes on a morphologic
image in a bladder cancer patient. Compared to the single color scheme ((a), “blackbody radiation”), the multicolor scheme “rainbow” in
(b) exaggerates subtle diﬀerences in Ktrans near color boundaries, creating artiﬁcial structures in the pseudocolor map. If the display range is
chosen too large, the parametric map is perceived as being more “homogeneous” due to underrepresentation of the spatial variation (c). A
small display range, on the other hand, tends to exaggerate the size of the “hotspot”, which may lead to an erroneous characterization of the
disease (d).
demonstrated to be eﬀective in hot-spot analysis include
signal enhancement ratio obtained at a ﬁxed time point
60–90 seconds postinjection [49] and the pharmacokinetic
parameter Ktrans [50].
Inspired by the commonly seen “rim enhancement” pat-
tern in solid tumors, some researchers also segment a tumor
into a poorly enhancing “core” and a strongly enhancing
“periphery” or “rim” [40, 51]. Benjaminsen et al. developed
this rough segmentation methodology into a quantitative
approachtodescriberadialheterogeneityintumorperfusion
[52]. In this method, a tumor parametric map is divided into
several concentric bands with approximately the same width.
Median or mean parameter values are calculated for each
band and plotted against band number or radius. The Rof-
stad group in Norway used this method to study the radial
distribution of tumor perfusion and EES fraction in a series
ofpreclinicalstudieswithhumanmelanomaxenograftsA-07
and R-18 between 2004 and 2008 [52–57]. At about the same
time, Jia et al. applied a similar method to the model-free
parameterwashoutslopeincolorectalcancerlivermetastasis,
and gave this approach an intuitive name “onion-peeling”
[32]. A major advantage of this method is that the radial
distributioncurvecanbenormalizedandcomparedbetween
parameters obtained with diﬀerent assessment techniques.
Therefore, it can be used as a validation approach. Graﬀ
et al. used this method to compare the radial distributions
of the DCE-MRI pharmacokinetic parameter EF and tumor
blood supply measured with a freely diﬀusible radioactive
tracer Na99mTcO4. The close match of radial distribution
curves partially validated the authors’ hypothesis that EF
measures tumor perfusion in these preclinical models [55].
Their results also showed that A-07 and R-18 xenografts
are characterized by diﬀerent radial distributions of EF [55]
andλ(aDCE-MRIpharmacokineticparameterproportional
to ve,[ 53]), suggesting a potential application in tumor
characterization.
Itshouldbenotedthatthesuccessofthe“onion-peeling”
method in Rofstad’s studies is partly due to their relatively
simple preclinical model. Growth of in vivo tumors may
be restricted or slowed down on certain directions by the
existing anatomical structures, leading to an irregular or
diﬀused tumor shape in which a “center” can hardly be6 Journal of Biomedicine and Biotechnology
(a) (b)
Figure 3: While the “onion-peeling” method has been demonstrated to be useful in animal xenografts, the speciﬁc assumption of radial
heterogeneity may not apply to all in vivo human tumors. It can only be used on lesions with regular shape and a radial enhancement
pattern (a). The lesion in (b) has an irregular, speculated shape that makes it diﬃcult to deﬁne its center. Its enhancement pattern is also
more stochastic, without a clear diﬀerence between the periphery and the tumor core. Applying the “onion-peeling” method to a tumor like
this will not generate much useful information about the underlying tumor biology.
deﬁned. Nonradial heterogeneity patterns are also frequently
seen in many human tumors (Figure 3). Therefore, this
method is probably working best in small scale preclinical
studies with well-controlled tumor growth conditions. In
large scale clinical studies, other quantiﬁcation methods that
are less speciﬁc about the heterogeneity pattern, such as the
texture analysis methods, might be more appropriate.
3.2. Histogram Analysis. Intratumoral heterogeneity is also
reﬂected by the shapes of parameter distribution histograms.
Tumors are typically characterized by a skewed distribution
with a long tail towards strong enhancement or high Ktrans
values.Multiple peaks maybe observed if thetumorcontains
a signiﬁcant fraction of poorly perfused hypoxic mass.
Disease progression is usually accompanied by an expansion
of the histogram to the right, with the peak broadening its
width but decreasing its height. A successful treatment, on
the contrary, “suppresses” the histogram leftwards, making
the peak narrower and more normal [30, 42]. Functional
principal component analysis also revealed that antiangio-
genic treatment with ZD6474 causes the disappearance of
as e c o n dp e a kw i t hh i g hKtrans values in mice bearing PC-3
human prostate adenocarcinoma xenografts [58]. A number
of studies have demonstrated that incorporating summary
statistics describing histogram width or asymmetry leads to
substantial improvement in disease diagnosis and response
assessment. In primary breast tumors, both the sensitivity
and speciﬁcity of malignant/benign lesion diﬀerentiation
can be improved by adding the Ktrans standard deviation
information to the conventional analysis approach using
Ktrans mean alone [59]. In another study, median Ktrans
was demonstrated to be less sensitive than the range of
the Ktrans histogram in predicting treatment response in
breast cancer patients receiving systemic chemotherapy [42].
Similar results were also reported in cervical cancer patients
receiving radiation therapy, where Mayr et al. found that
the 10th percentile of RSI is a better predictor for tumor
recurrence than the mean or median values [60].
So far, there is no consensus on the optimal method
for histogram analysis. Some researchers perform a bin-to-
bin comparison between two normalized histograms [61].
Although the rationale for this approach is straightforward
to understand, it is in general an ineﬃcient technique: a
certain number of bins are needed for the histogram to
accurately reﬂect the shape of the underlying distribution.
In clinical research, this number is typically between 10 and
30. When all these bins are simultaneously compared, the
need for multicomparison correction makes the whole test
very insensitive. For example, if an overall signiﬁcance level
of 0.05 is assigned to a comparison between two normalized
histograms with 20 bins each, the individual signiﬁcance
level for every single bin will be only 0.05/20 = 0.0025
with the basic Bonferroni correction [62]. With such a low
individual signiﬁcance level, subtle changes in the histogram
are very likely to be masked.
A better strategy for histogram analysis is to summarize
only the most relevant information into a few descriptive
quantities. Almost all summary statistics have been used
in the literature to describe the distribution histogram. A
partial list includes the range [42], mean, median, standard
deviation [59], skewness [9], kurtosis [63], entropy [63], and
various percentiles [30, 41, 43, 60, 64]. There is no decisive
conclusion about which statistics is the best. However, the
percentiles are probably more robust than the range and
moment statistics on pharmacokinetic parametric maps. An
“allowed range” is usually set for each pharmacokinetic
parameter by the iterative ﬁtting algorithm to accelerate
convergence. If the true range of the actual distribution is
wider than this “allowed range”, the long tails outside the
allowed range will be truncated and replaced by artiﬁcial
“peaks” on the maximum or minimum allowed values.Journal of Biomedicine and Biotechnology 7
Unlike the range and moment statistics, the percentiles are
insensitive to this artiﬁcial distortion of histogram shape
because they are not aﬀected by changes in a few extreme
values.
3.3. Texture Analysis. The histogram analysis only looks
at the distribution of individual voxels within a tumor
ROI. The spatial correlation between voxels is ignored.
Theoretically, a tumor with an enhancing rim could have an
identical histogram with a tumor having many enhancing
foci scattered over the entire mass. Spatial distribution
information is needed to better diﬀerentiate lesions with
similar histogram but distinctive enhancement patterns. A
number of studies have been conducted along this direction
using image texture analysis techniques [31, 65–70].
In DCE-MRI data analysis, the most frequently used
textureanalysistechniqueisthecooccurrencematrixmethod
ﬁrst described by Haralick et al. [71]. Brieﬂy speaking,
the cooccurrence matrix element Pd,θ(i, j) measures the
probability of starting from any voxel with value i in an
image, moving d voxels along direction θ, and arriving at
another voxel with value j. Therefore, the cooccurrence
matrix is a two dimensional histogram describing a joint
distribution of all possible moves with step size d and
direction θ on the image. Textural features, such as contrast
and correlation, can be exacted from this 2D histogram.
They are then averaged over four directions (θ = 0◦,4 5 ◦,
90◦, and 135◦) to remove angular dependency. In medical
imagingstudies,thestepsized isusuallytakenas1voxel.The
voxel values are usually discretized to reduce cooccurrence
matrix dimension. Sinha et al. used this technique to
obtain eight textural features that made a reasonably good
discrimination (speciﬁcity 70%, sensitivity 75%) between 20
malignant and 23 benign breast lesions [65]. Chen et al.
extended Haralick et al. 2D technique to 3D, and achieved a
signiﬁcant improvement in classiﬁcation performance using
features obtained from a volumetric texture analysis in a
cohort of 77 malignant and 44 benign lesions [66]. Positive
results were also reported with various model-free [31]
and pharmacokinetic parametric maps [67]a sw e l la so n
four dimensional dynamic series [68]. Nie et al. further
associated the textural features (gray level entropy and sum
average) with the visual descriptors in BI-RADS lexicon
(enhancementintensityandinternalenhancementpatterns),
thus giving the highly mathematical approach an intuitive
interpretation [69].
Currently, the major problem associated with DCE-MRI
texture analysis is the high dimensionality of the feature
space. A more detailed discussion of this issue will be
given in the next section. Researchers are encouraged to
adopt a concise study design and dimensionality reduction
techniques to improve the reliability of their conclusions.
3.4. Spatial-Parametric Hypervolume Geometry. An interest-
ing approach of heterogeneity quantiﬁcation was described
in the exploratory works of Rose et al. [35, 36]. In their
approach, DCE-MRI pharmacokinetic parameters were not
treated in the conventional way as voxel values in a 3D
imaging volume. Instead, they were interpreted as the
height on a fourth dimension in an “extruded” 4D binary
hypervolume. Geometric features like (hyper-)surface area,
(hyper-)volume, (hyper-)surface to (hyper-)volume ratio,
and box-count fractal dimension can be calculated for this
spatial-parametric hypervolume, and used as quantitative
descriptors of tumor vascular heterogeneity [35]. In a recent
study, the R´ enyi family of fractal dimensions was also
investigated [36]. Although the small sample sizes prevented
any decisive conclusion about its value to be made at this
moment,initialresultsingliomagradingandlivermetastasis
treatment response seem to be promising.
This method is conceptually interesting in that spatial
and parametric information are treated equally as dimen-
sions in the 4D hypervolume. Geometric features of the
hypervolume thereby describe variations in both spatial and
parametric domains by nature. BI-RADS lexicon suggests
that both morphologic and heterogeneity information are
critical in diagnosis of breast cancer. This is perhaps
true for all solid tumors. Therefore, geometric features
of the spatial-parametric hypervolume compose a pool
of potential biomarkers that can simultaneously quantify
tumor morphology and heterogeneity. Such a biomarker, if
identiﬁed, may have important uses in tumor diagnosis and
response prediction because it can improve the robustness
of the classiﬁer/predictor through reduction of input space
dimensionality.
4.Technological and
Methodological Considerations
4.1. Avoid Data Sparsity in Study Design. Many descriptive
and textural features of imaging data can be extracted from
theanalysisoftumorheterogeneity.Someresearcherstendto
use a large number of features in their studies. In an extreme
example we found more than 600 features were investigated
in only 23 patients [70]. While the researchers’ desire of get-
ting the maximum yield from their data is understandable,
this practice is fundamentally problematic because as the
number of features increases, the problem of data sparsity
arises due to Bellman’s “curse of dimensionality” [72]. A
sparsely-distributed sample set cannot provide adequate
information to fully represent the complex behaviors in a
large population. Consequently, any prediction made from
such a sample set is highly unstable and thus practically
useless [73]. This problem is probably responsible for our
ﬁnding that some complex discriminators are claimed to
have (artiﬁcially) excellent performance in a relatively small
patient population but never develop into real clinical
application.
There is no real remedy for the sparse data problem
except for thorough consideration and careful planning in
the designing stage of a study. The number of features used
for classiﬁcation or prediction must be strictly controlled
from the very beginning. A rule of thumb is to keep the ratio
betweenthenumberofpatientsineachclassandthenumber
of features above 10 [74], that is, for a typical study of about
100 patients divided into two groups, the number of features8 Journal of Biomedicine and Biotechnology
thatcanbeinvestigatedshouldnotexceedﬁve.Thisstringent
restriction requires the investigators to include only the most
promising features into their analysis rather than use all the
parameterstheycangetunselectively.Ofcourse,information
about the other less promising features is also interesting and
may lead to important discoveries. We recommend to report
those as exploratory data. No eﬀo r ts h o u l db em a d et og e t
any statistical inference from these data. In this way, these
data can be preserved without harming the statistical power
of the whole study. They may serve as part of the raw data
set for future metaanalyses which may provide statistically
meaningful information that can never be derived from any
single study.
Some researchers chose to classify individual voxels
instead of the whole tumor or subject [67, 68, 75]. While this
method does help to greatly reduce the stringent restriction
on feature set size, caution is needed in the interpretation of
the results. Simply stating that a voxel has a “responder-like”
curve or “benign” parameters is superﬁcial and sometimes
misleading. It is more preferable to characterize voxels with
imaging features that have well-recognized association with
tumor biology on cellular or tissue levels. Correlation with
other established biomarkers is also important when such
information is available.
Dimensionality reduction techniques are also powerful
tools that may help the investigators to ﬁght the “curse
of dimensionality” [74]. It should be noted that dimen-
sionality reduction techniques are only supplements to, but
not replacement for, careful study design and successful
dimensionality control. They should only be applied to a
small feature set carefully selected according to the rule
of thumb mentioned above. Applying a dimensionality
reduction technique to a poorly designed study would not
add any strength to its conclusions.
4.2. Need for Standardization in DCE-MRI Data Acquisition
and Analysis. Currently there is no “standard” way of
performing DCE-MRI. A number of methodologies have
been developed by diﬀerent groups. Some of them use a
T1-weighted fast low-angle shot (FLASH) sequence [76],
whiletheothersusesaturationrecoveryorinversionrecovery
techniques [77]. The measured signal intensities may be
converted to gadolinium concentration through the use of
a calibration phantom [78], calculation of relative signal
enhancement [79], or precontrast T1 [80]o rp r o t o nd e n s i t y
measurements [81]. Data analysis methods are about equally
variable, too. Many model-free and pharmacokinetic param-
eters have been described in the literature (Tables 1 and 2).
Most model-free parameters do not have a clear deﬁnition
that is strictly followed within the DCE-MRI community.
For example, many investigators reported the model-free
parameter area-under-the-curve (AUC) in their studies, but
the way they measured it can be quite diﬀerent: in some
studies it was measured from the relative signal enhance-
ment dynamic curve, while in the others the gadolinium
concentration dynamic curve was used. The measurement
timecanalsovaryfrom30to180secondspostinjection.Even
though pharmacokinetic parameters are generally better
deﬁned than model-free parameters, considerable variability
still exists in the choice of the pharmacokinetic models [22–
26] and deconvolution techniques [82, 83].
It is known that many factors in data acquisition and
analysis can substantially aﬀect the reliability of results
in DCE-MRI studies. The accuracy and precision of the
pharmacokinetic parameter estimates, for example, are
largely determined by the signal-to-noise ratio (SNR) and
temporal resolution of the MR sequence [84]. Systematic
errors can be introduced from various sources, such as
voluntary or involuntary patient motion, inappropriate use
of postprocessing ﬁlters, inhomogeneity in B1 excitation
ﬁeld and receiver coil sensitivity, breakdown of linearity in
the gadolinium concentration calibration curve [85], and
unequal deﬁnitions of the same pharmacokinetic parameter
(such as Ktrans)i nd i ﬀerent models [22, 23]. Therefore, the
methodological variability described above actually contains
a large number of potential error sources. Their complex yet
poorly understood interaction makes it extremely diﬃcult
to compare DCE-MRI data from diﬀerent sources. This
problem is especially important in the study of tumor vas-
cular heterogeneity. As we have mentioned in the discussions
above, an individual study can only investigate a very small
fraction of all parameters that characterize intratumoral
heterogeneity. The only way to accelerate the investigation
process is through meta-analysis that combines results from
diﬀerent studies. Obviously, this can only be achieved
with high quality data acquired and analyzed following an
optimized standard procedure.
A standardization eﬀort is currently underway driven by
the DCE-MRI subcommittee of the Radiological Society of
North American (RSNA) Quantitative Imaging Biomarkers
Alliance (QIBA) initiative [86]. The most recent progress
of their collaborative eﬀort is a comprehensive technical
proﬁle that speciﬁes basic standards in DCE-MRI data
acquisition,analysis,andqualitycontrolon1.5Teslasystems.
It is recommended that DCE-MRI should be performed
on a clinical scanner qualiﬁed with a standard phan-
tom, using a 3D FLASH or equivalent sequence without
any magnetization preparation or postprocessing ﬁlter.
The image intensity should be converted to gadolinium
concentration through the use of a variable ﬂip angle
precontrast T1 map [87] after necessary corrections for
patient motion and inhomogeneity in B1 ﬁeld or coil
sensitivity. The pharmacokinetic parameter Ktrans (estimated
with the standard Tofts’ model) and model-free parameter
IAUGC (AUC measured from the gadolinium concentration
curve up to 90 seconds postinjection) are recommended as
standard quantitative endpoints that should be employed
in clinical trials and practice. Guidelines on the minimally
acceptable and ideal ranges of various scan parameters (like
temporal resolution and slice thickness) are also provided.
Investigators in this area are encouraged to follow the
progress of the QIBA initiative through journal publications
and online updates (http://qibawiki.rsna.org/index.php?title
=DCE-MRI subctte), and adopt the most up-to-date con-
sensus to their own studies to ensure their data have
the highest quality standard and the maximum level of
comparability.Journal of Biomedicine and Biotechnology 9
An important issue that is not addressed in the present
version of QIBA DCE-MRI proﬁle is the lack of quality con-
trol in the vascular parameter ﬁtting stage. Many researchers
only report the “best ﬁt” estimates for pharmacokinetic
parameters and ignore the inherent uncertainty in those
estimates. This practice leads to a substantial underestima-
tion of the variability in pharmacokinetic parameters. It
also raises a philosophical question whether it is appropriate
to treat reliable and unreliable parameter estimates equally
in the assessment of tumor heterogeneity. Hence, we sug-
gest that DCE-MRI researchers should always report the
asymptotic conﬁdence intervals with the “best ﬁt” estimates
for pharmacokinetic parameters, and adopt an exclusion
criterion or weighting scheme that controls the inﬂuence of
unreliable estimates from noisy data. We also expect that
as the awareness of this issue is raised, a consensus will be
developed through the collective eﬀort of the whole DCE-
MRI community, and will be included in future standards.
4.3. Validation. It is diﬃcult to validate DCE-MRI param-
eters because they measure a mixed eﬀect of blood ﬂow,
microvascular permeability, and EES volume. A number
of studies have demonstrated broad correlations between
various DCE-MRI parameters and tissue perfusion [88],
microvascular density (MVD) [45, 89], or angiogenic factor
expression [90]. However, controversial results are also
reported in the literature [91–93]. One reason for this
controversy might be tumor heterogeneity at the subvoxel
level. In a human cervical carcinoma xenograft study,
matched DCE-MRI images and histological sections showed
substantial intravoxel heterogeneity in morphology and
tissue composition, even though the voxel size (0.23 × 0.47
× 2.0mm3) is already ten times smaller than those used in
human studies [94]. Therefore, DCE-MRI parameters may
be better validated against immunohistochemical measure-
ments averaged over several ﬁelds randomly picked from the
region of interest.
Beside the ROI-averaged parameter values, the distri-
bution of DCE-MRI parameters also needs to be validated
in studies of tumor vascular heterogeneity. This task is
relatively simple if the “gold standard” is another imaging
modality with similar spatial resolution, for which direct
comparison can be made between summary statistics [95],
histogram shapes, or certain heterogeneity patterns [52, 55].
MVD values or angiogenic factor expression levels need to
be compared with DCE-MRI parameters within multiple
subregional ROIs or along a line proﬁle. Special techniques,
like MRI-guided biopsy [96], may be used to help reduce
sampling error caused by mismatch between DCE-MRI
images and histological slides.
5. Conclusion
Experimental evidence shows that vascular heterogeneity
plays an important role in tumor biology. Several methods
have been developed to quantify tumor vascular heterogene-
ity with DCE-MRI. Initial studies in patients and animal
models have shown promising results in disease diagnosis,
tumor grading, and response assessment. These results give
us additional understanding of tumor biology and justify the
necessity of continuous development along this direction.
However, the quality of a DCE-MRI heterogeneity study
can easily be undermined by various methodological and
technological issues, such as poor study design or lack of
standardization. This paper may serve as a guideline to help
investigatorsunderstandandalsoavoidthesepossiblepitfalls
in study design, data acquisition, and analysis in future
studies of tumor vascular heterogeneity.
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